Cargando…

Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist’s Perspective

Antibody-drug conjugates (ADCs) appear to be in a developmental boom, with five FDA approvals in the last two years and a projected market value of over $4 billion by 2024. Major advancements in the engineering of these novel cytotoxic drug carriers have provided a few early success stories. Althoug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lucas, Andrew T., Moody, Amber, Schorzman, Allison N., Zamboni, William C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395454/ https://www.ncbi.nlm.nih.gov/pubmed/34449544 http://dx.doi.org/10.3390/antib10030030

Ejemplares similares

Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
por: Lucas, Andrew T., et al.
Publicado: (2019)

Factors Affecting the Pharmacology of Antibody–Drug Conjugates
por: Lucas, Andrew T., et al.
Publicado: (2018)

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2017)

Artificial intelligence in drug development: clinical pharmacologist perspective
por: Jang, In-Jin
Publicado: (2019)

Perspectives on training quantitative systems pharmacologists
por: Zhang, Tongli, et al.
Publicado: (2022)

The pharmacologist’s fertility
por: Papadimos, Thomas J.
Publicado: (2013)

Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
por: Kamath, Amrita V., et al.
Publicado: (2014)

Sports Pharmacology: A Medical Pharmacologist’s Perspective
por: Malve, Harshad O.
Publicado: (2018)

Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations
por: Shim, Hyunbo
Publicado: (2020)

Drugs in sport: The curse of doping and role of pharmacologist
por: Mahendru, Dhruv, et al.
Publicado: (2019)

Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates
por: Fisher, J. Edward
Publicado: (2021)

Clinical pharmacologist from the eyes of a clinical pharmacologist: a questionnaire-based survey
por: Krishnamurthy, Manjunath Nookala, et al.
Publicado: (2022)

Push, promote or educate…musings of a pharmacologist on drug promotion
por: Shashindran, Chanolean
Publicado: (2014)

Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
por: Wu, Mo, et al.
Publicado: (2022)

ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates
por: Mou, Si, et al.
Publicado: (2018)

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
por: D’Arienzo, Andrea, et al.
Publicado: (2023)

Statistics and experimental design for toxicologists and pharmacologists /
por: Gad, Shayne C., 1948-
Publicado: (2005)

Most cherished moments of STAR pharmacologists
por: Rathnam, Shivprakash, et al.
Publicado: (2021)

2′-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model
por: Peng, Lei, et al.
Publicado: (2014)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Reorientation program on research methodology for Ayurveda academicians: A clinical pharmacologist's perspective
por: Ramakrishna, Suresh K.
Publicado: (2012)

An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians’ Perspective
por: Schmidt, Carsten, et al.
Publicado: (2021)

Interrogating heterogeneity of cysteine-engineered antibody-drug conjugates and antibody-oligonucleotide conjugates by capillary zone electrophoresis-mass spectrometry
por: Xu, Tian, et al.
Publicado: (2023)

Role of pharmacologists in clinical research: The onus is on us
por: Singh, Jagjit
Publicado: (2013)

Louis Lewin, Pharmacologist, Toxicologist, Medical Historian
por: Macht, David I.
Publicado: (1931)

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2020)

Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020)

Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
por: Agarwal, Paresh, et al.
Publicado: (2014)

Antibody–Drug Conjugates for Cancer Therapy
por: Parslow, Adam C., et al.
Publicado: (2016)

Introduction to Antibody-Drug Conjugates
por: Pettinato, Mark C.
Publicado: (2021)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

Herbal Medicines: Can We Do Without Pharmacologist?
por: Calapai, Gioacchino, et al.
Publicado: (2007)

Low Affinity GPCRs for Metabolic Intermediates: Challenges for Pharmacologists
por: Smith, Nicola J.
Publicado: (2012)

Triptans: the experience of a clinical pharmacologist in clinical practice
por: Pini, Luigi Alberto, et al.
Publicado: (2001)

Educating and training India's next generation of in vivo pharmacologists
por: Lewis, David I.
Publicado: (2016)

Prof. K. P. Gupta: An exemplary pharmacologist of India
por: Rahman, Syed Ziaur
Publicado: (2017)

Kinoscope: An Open-Source Computer Program for Behavioral Pharmacologists
por: Kokras, Nikolaos, et al.
Publicado: (2017)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021)

Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates
por: Abdollahpour-Alitappeh, Meghdad, et al.
Publicado: (2017)

Cysteine metabolic engineering and selective disulfide reduction produce superior antibody-drug-conjugates
por: Procopio-Melino, Renée, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3998ravjn7heusgkngok2s9287